Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation
A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use…